HTG Molecular Diagnostics, Inc. a commercial stage life sciences company, focuses on the precision medicine. The company offers instrumentation; consumables comprising assay kits; and software that automate sample processing and profiles various molecular targets. Its platforms generate a molecular profiling library for detection using next-generation sequencing. The company's marketed panels include HTG EdgeSeq precision immuno-oncology panel; HTG EdgeSeq miRNA whole-transcriptome assay; HTG EdgeSeq DLBCL cell of origin assay EU; HTG EdgeSeq DLBCL cell of origin assay; HTG lung fusions assay; HTG EdgeSeq ALKPlus assay EU; HTG immune response panel; and HTG mouse mRNA tumor response panel. It serves biopharmaceutical companies, academic research centers, and molecular testing laboratories. HTG Molecular Diagnostics, Inc. distributes its instruments and consumables directly in the United States and Europe; and through distributors in parts of Europe and internationally. The company has a governing agreement with QIAGEN Manchester Limited; and an agreement with Illumina, Inc. for the development of nuclease-protection-based RNA or DNA profiling tests. The company was formerly known as HTG, Inc. and changed its name to HTG Molecular Diagnostics, Inc. in March 2011. HTG Molecular Diagnostics, Inc. was incorporated in 1997 and is based in Tucson, Arizona.
IPO Year: 2015
Exchange: NASDAQ
Website: htgmolecular.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2022 | $5.00 → $8.00 | Hold → Buy | Craig-Hallum |
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
10-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
8-K - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Filer)
Craig-Hallum upgraded HTG Molecular Diagnostics from Hold to Buy and set a new price target of $8.00 from $5.00 previously
SVB Leerink reiterated coverage of HTG Molecular Diagnostics with a rating of Outperform and set a new price target of $10.00 from $15.00 previously
HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $9.00 from $11.00 previously
HC Wainwright & Co. reiterated coverage of HTG Molecular Diagnostics with a rating of Buy and set a new price target of $11.00 from $15.00 previously
TUCSON, Ariz., May 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced that its management team will present the advantages of its proprietary drug discovery engine at the 2023 Biotechnology Innovation Organization (BIO) International Convention and will host in-person meetings during the remaining days of the June 5 – 8, 2023 event in Boston, MA. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treat
TUCSON, Ariz., May 16, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported achievement of another technical milestone in its drug discovery business. HTG is pioneering a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. HTG's objective is to develop best-in-class molecules for the treatment of diseases, with the ability to apply its platform agnostically across therapy areas. At the center of this approach is HTG's proprietary RNA profiling technologies, functionally married with an adva
TUCSON, Ariz., May 10, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today reported financial results for the quarter ended March 31, 2023 and provided recent drug discovery business highlights. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel artificial intelligence ("AI")-driven platform. This unique drug can
TUCSON, Ariz., April 25, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today provided an update on partnering discussions for its drug discovery business unit. HTG has pioneered a proprietary platform-based approach that is designed to help improve drug discovery, referred to as transcriptome-informed drug discovery and design. At the center of this approach is the application of HTG's proprietary RNA profiling technologies, functionally married with advanced medicinal chemistry using a novel AI-based platform. This unique drug candidate optimization platform is expected to allow for more biolo
TUCSON, Ariz., April 18, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a platform-based life science tools and drug discovery company, today announced the achievement of three significant drug discovery business milestones in the first quarter of 2023. As reported in January 2023, HTG filed a patent application on December 28, 2022, which included claims directed toward specific compounds, pharmaceutical compositions and methods of treating or preventing disease by administration of the compounds for its first target and indication. These compounds were designed by the company's advanced machine-learning medicinal chemistry platform using a target-first a
TUCSON, Ariz., Jan. 09, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today provided an update on the progress of its drug discovery business unit, including the filing of a patent application directed towards its first therapeutics target, and announced that its management team will be hosting in-person meetings at the LifeSci Partners 2023 Corporate Access Event from January 9-11, 2023 in San Francisco, CA. HTG Therapeutics, the company's drug discovery business unit, has been actively using its transcriptome
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash
TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, provides here a summary of its second HTG Therapeutics key opinion leader (KOL) webinar: "The Role of RNA Profiling in Drug Discovery and Analysis," hosted on Tuesday, December 13, 2022. In this latest webinar, Dr. Robert Spitale of the University of California, Irvine, delved into the many potential roles for RNA profiling in drug discovery and development and how it can be leveraged to improve the selection of lead compounds. Dr. Spitale d
TUCSON, Ariz., Dec. 23, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the closing of its previously announced public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants have a
TUCSON, Ariz., Dec. 21, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced the pricing of a public offering of an aggregate of 1,290,322 shares of its common stock (or pre-funded warrants in lieu thereof), Series A-1 warrants to purchase up to 1,290,322 shares of common stock and Series A-2 warrants to purchase 1,290,322 shares of common stock, at a combined public offering price of $7.75 per share (or pre-funded warrant) and accompanying warrants. The Series A-1 warrants will have an exercise price o
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
3 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
4 - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Issuer)
Preliminary full year 2022 unaudited revenue of $6.4 million Cash and cash equivalents of $12.2 million as of December 31, 2022 TUCSON, Ariz., Jan. 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced certain preliminary, unaudited financial results for the year ended December 31, 2022. Total revenue for the full year 2022 is expected to be approximately $6.4 million, including approximately $2.7 million of HTG Transcriptome Panel (HTP) revenue representing 42% of our total revenue. Cash and cash
TUCSON, Ariz., Aug. 11, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended June 30, 2022. Throughout the quarter ended June 30, 2022, the Company's technology and strategic development efforts were highlighted in a number of customer and KOL presentations and publications including, but not limited to, the following: A webinar titled "Integration of the HTG Transcriptome Panel into Preclinical and Clinical Programs to Drive Precision Medicine Research" fe
TUCSON, Ariz., Aug. 04, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended June 30, 2022 after the market close on Thursday, August 11, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, August 11Time:4:30pm ETToll Free:1-800-954-0602 International:1-212-231-2936 Conference ID:2
TUCSON, Ariz., May 12, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported recent business highlights and financial results for the quarter ended March 31, 2022. Recent Business Highlights Released a proof-of-approach white paper, demonstrating the utility of HTG's proprietary profiling technologies as a key component of its novel drug discovery and design platform. Expanded the HTG Therapeutics business unit leadership team with the addition of Christina M. Carruthers, Ph.D., as Vice President of Target Strategy and Early Developmen
TUCSON, Ariz., May 05, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the quarter ended March 31, 2022 after the market close on Thursday, May 12, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Thursday, May 12Time:4:30pm ETToll Free:1-855-327-6837 International:1-631-891-4304Conference ID:10019008
TUCSON, Ariz., March 29, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the year ended December 31, 2021. Recent Business Highlights HTG Transcriptome Panel ("HTP") revenue continued to increase in the fourth quarter of 2021, ending the year as the top selling assay at approximately 16% of total revenue, just 5 months after commercial sales availability. Announced the expansion of its therapeutics team with the addition of several highly experienced professionals, led by Stephen Barat, Ph.D., a drug dev
TUCSON, Ariz., March 22, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today announced that it will report its financial results for the year ended December 31, 2021 after the market close on Tuesday, March 29, 2022. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30pm Eastern Time. Details for the conference call are as follows: Conference Call & Webcast Details Date:Tuesday, March 29Time:4:30pm ETToll Free:1-855-327-6837International:1-631-891-4304Conference ID:10018
Preliminary full year 2021 unaudited revenue of $8.9 million Cash, cash equivalents and short-term marketable securities of $21.9 million as of December 31, 2021 TUCSON, Ariz., Jan. 06, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced certain preliminary, unaudited financial results for the year ended December 31, 2021. Total revenue for the full year 2021 is expected to be approximately $8.9 million, including approximately $1.4 million of HTG Transcriptome Panel (HTP) revenue. Cash, cash equivalents and short-term marketable securities are approximately $21.9 million as
TUCSON, Ariz., Nov. 10, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling technology, today reported its financial results for the quarter ended September 30, 2021. Recent Business Highlights Total revenue for the quarter ended September 30, 2021 increased by approximately 42% when compared to the same period in 2020. HTG Transcriptome Panel revenue increased in the third quarter and accounted for 27% and 18% of consumables product revenue for the three and nine months ended September 30, 2021, respectively.Continued collaboration with participants in the Ea
TUCSON, Ariz., Nov. 02, 2021 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (NASDAQ:HTGM), a life science company advancing precision medicine through its transcriptome-wide technology, today announced that it will report its financial results for the third quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021. Management will also host a conference call with investors to discuss financial results and provide a corporate update at 4:30 pm ET. Conference Call & Webcast DetailsDate:Wednesday, November 10Time: 4:30 pm ETToll Free:877-407-0789 International:201-689-8562Conference ID:13723995Webcast:https://78449.themediaframe.com/dataconf/productusers/vvd
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13D/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13D/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13D - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
SC 13G/A - HTG MOLECULAR DIAGNOSTICS, INC (0001169987) (Subject)
Gainers Jin Medical International (NASDAQ:ZJYL) stock rose 58.4% to $13.51 during Monday's regular session. The current volume of 4.2 million shares is 8924.5% of Jin Medical International's average full-day volume over the last 100 days (last updated at 13:30 EST). The company's market cap stands at $104.7 million. Chinook Therapeutics (NASDAQ:KDNY) stock rose 58.31% to $37.98. Trading volume for this security as of 13:30 EST is 17.3 million, which is 2476.2% of its average full-day volume over the last 100 days. The company's market cap stands at $2.5 billion. Aesthetic Medical Intl (NASDAQ:AIH) stock rose 22.91% to $1.18. Trading volume for Aesthetic Medical Intl's stock is 542.6K as o
Gainers Asset Entities Inc. (NASDAQ:ASST) shares jumped 142% to $2.79 after the company announced the development of an AI bot as part of its AE360DDM suite of services on Discord. Micromobility.com Inc. (NASDAQ:MCOM) shares rose 91.2% to $0.44. Chinook Therapeutics, Inc. (NASDAQ:KDNY) jumped 55.9% to $37.40 after Novartis agreed to acquire the company for $40 per share in cash. Advanced Health Intelligence Ltd. (NASDAQ:AHI) shares gained 44% to $3.14 after jumping 581% on Friday. Auddia Inc. (NASDAQ:AUUD) shares climbed 39.4% to $0.6042. Auddia reported the launch of its faidr 3.0 mobile app. Infobird Co., Ltd (NASDAQ:IFBD) shares climbed 38.8% to $2.02. Infobird recently regaine
Gainers Avalo Therapeutics (NASDAQ:AVTX) shares rose 17.3% to $3.53 during Wednesday's regular session. The company's market cap stands at $46.5 million. Journey Medical (NASDAQ:DERM) shares rose 15.59% to $1.84. Trading volume for this security as of 13:30 EST is 55.9K, which is 228.4% of its average full-day volume over the last 100 days. The company's market cap stands at $33.3 million. Societal CDMO (NASDAQ:SCTL) shares rose 15.14% to $0.9. Trading volume for Societal CDMO's stock is 81.4K as of 13:30 EST. This is 43.5% of its average full-day volume over the last 100 days. The company's market cap stands at $76.2 million. Microbot Medical (NASDAQ:MBOT) stock moved upwards by 14.79%
On Wednesday, 29 companies set new 52-week lows. Interesting Highlights From Today's 52-Week Lows: The largest company in terms of market cap to set a new 52-week low was NovoCure (NASDAQ:NVCR). The company with the smallest market cap to set a new 52-week low was HTG Molecular Diagnostics (NASDAQ:HTGM). PolarityTE (NASDAQ:PTE)'s stock traded down the lowest, falling 42.87% to reach a new 52-week low. Owlet (NYSE:OWLT) shares rebounded the highest, with shares trading up 0.1%, bouncing back after reaching its new 52-week low. Here is a list of stocks that set new 52-week lows on Wednesday: NovoCure (NASDAQ:NVCR) shares were down 1.26% for the day, having made a 52-week low of
On Tuesday, 69 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Estee Lauder Cos (NYSE:EL) was the largest company by market cap to set a new 52-week low. The smallest company by market cap to hit a new 52-week low was Biodexa Pharmaceuticals (NASDAQ:BDRX). Westport Fuel Systems (NASDAQ:WPRT) shares dropped the most, trading down 848.41% to reach its new 52-week low. Greenidge Generation Hldg (NASDAQ:GREE) shares rebounded the highest, with shares trading up 0.0%, bouncing back after reaching its new 52-week low. The following stocks created new 52-week lows on Tuesday: Estee Lauder Cos (NYSE:EL) shares set a new 52-week low of $178.78. The stock trade
HTG Molecular Diagnostics (NASDAQ:HTGM) stock is down on Tuesday after the company announced a Chapter 11 bankruptcy filing. According to the filing, HTG Molecular Diagnostics will operate as a "debtor-in-possession" business during the bankruptcy. It's also seeking a variety of first-day motions that will allow it to continue normal operations. The filing also accelerates the obligations of the company's debts, including a $2.68 million loan held by Silicon Valley Bank, now a division of First-Citizens Bank and Trust Company. HTG Molecular Diagnostics notified the termination of Senior Vice President and Chief Commercial Officer Byron Lawson at the start of the month. However, the
Gainers Hoth Therapeutics (NASDAQ:HOTH) shares moved upwards by 66.5% to $3.13 during Tuesday's regular session. Trading volume for this security as of 13:30 EST is 88.5 million, which is 38144.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $10.3 million. Synlogic (NASDAQ:SYBX) stock rose 25.39% to $0.61. As of 13:30 EST, Synlogic's stock is trading at a volume of 413.1K, which is 135.4% of its average full-day volume over the last 100 days. The company's market cap stands at $41.6 million. Castle Biosciences (NASDAQ:CSTL) shares moved upwards by 23.62% to $14.41. Castle Biosciences's stock is trading at a volume of 3.1 million
Gainers Recruiter.com Group, Inc. (NASDAQ:RCRT) shares jumped 114% to $0.41. Recruiter.com signed a definitive agreement for planned purchase of fintech assets of GoLogiq. Hoth Therapeutics, Inc. (NASDAQ:HOTH) rose 96% to $3.6850 after the company announced preclinical results for HT-ALZ for the treatment of Alzheimer's disease. Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) shares rose 37.8% to $0.5928. Zura Bio Limited (NASDAQ:ZURA) shares gained 25% to $8.11 after the company completed approximately $80 million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual antagonist. Xunlei Limited (NASDAQ:XNET) rose 22%
Gainers Hoth Therapeutics (NASDAQ:HOTH) shares rose 99.5% to $3.75 during Tuesday's pre-market session. The company's market cap stands at $12.3 million. Novo Integrated Sciences (NASDAQ:NVOS) stock increased by 22.15% to $0.15. The market value of their outstanding shares is at $22.3 million. T2 Biosystems (NASDAQ:TTOO) stock increased by 18.14% to $0.08. The market value of their outstanding shares is at $2.0 million. Medigus (NASDAQ:MDGS) stock rose 16.61% to $5.14. The company's market cap stands at $8.4 million. Zura Bio (NASDAQ:ZURA) shares rose 15.55% to $7.5. The company's market cap stands at $238.5 million. PDS Biotechnology (NASDAQ:PDSB) shares increased by 13.16% to $7.39.
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ:VEDU) shares rose 85.8% to $0.7985 in pre-market trading. Chijet Motor Company, Inc. (NASDAQ:TTOO) shares surged 51.3% to $0.1060 in pre-market trading after dipping around 31% on Monday. T2 Biosystems reported submission for the FDA breakthrough device designation for candida auris diagnostic test. Secoo Holding Limited (NASDAQ:SECO) gained 35.8% to $1.100 in pre-market trading. Zura Bio Limited (NASDAQ:ZURA) shares gained 35.4% to $8.79 in pre-market trading after the company completed approximately $80 million financing with the focus on advancing ZB-106, a potential first-in-class anti-IL-17 and anti-BAFF dual ant